Circuit Reaffirms Invalidity of Pfizer's Norvasc Patent
A circuit court on Tuesday reaffirmed that a Pfizer Inc. patent for popular hypertension drug Norvasc is invalid by overturning a patent infringement ruling against Mylan Laboratories Inc....To view the full article, register now.
Already a subscriber? Click here to view full article